RESUMO
BACKGROUND: The global shift in healthcare during the COVID-19 pandemic led to challenges in the care of people living with HIV. METHODS: We conducted a retrospective study that aimed to delineate sociodemographic, clinical characteristics and outcomes, of people living with HIV diagnosed with ocular syphilis. RESULTS: Fifty-three people living with HIV were identified with ocular syphilis. Thirty-eight (71.6%) presented ocular symptoms. Twenty-three (43.3%) underwent lumbar puncture, 5 (9.4%) were positive for neurosyphilis. Forty-seven (88.6%) received treatment, 32 (68%) received standard treatment with aqueous crystalline penicillin G, and 15 (31.9%) were treated with alternative regimens due to the impossibility of hospitalization. Six (11.3%) individuals were lost to follow-up and/or did not receive treatment. Eighteen (56.2%) out of 32 individuals in the aqueous crystalline penicillin G group experienced serological response, 5 (15.6%) experienced treatment failure, and 9 (28.1%) were lost to follow-up. In the alternative therapy group, 12 out of 15 individuals (80%) experienced serological response. One (6.7%) experienced treatment failure, and 2 (13.3%) were lost to follow-up. CONCLUSIONS: During the COVID-19 health emergency in Mexico, alternative treatments for ocular syphilis demonstrated favorable clinical outcomes amid challenges in accessing hospitalization.
Assuntos
COVID-19 , Infecções por HIV , Sífilis , Humanos , Masculino , Feminino , Estudos Retrospectivos , COVID-19/epidemiologia , COVID-19/complicações , Adulto , Infecções por HIV/tratamento farmacológico , Infecções por HIV/complicações , Pessoa de Meia-Idade , Sífilis/tratamento farmacológico , Sífilis/complicações , Sífilis/epidemiologia , SARS-CoV-2 , Antibacterianos/uso terapêutico , Infecções Oculares Bacterianas/epidemiologia , Infecções Oculares Bacterianas/tratamento farmacológico , Resultado do Tratamento , Neurossífilis/tratamento farmacológico , Neurossífilis/complicações , Neurossífilis/epidemiologia , Penicilina G/uso terapêuticoAssuntos
Infecções por HIV , Mpox , Sífilis , Humanos , Sífilis/diagnóstico , Infecções por HIV/complicaçõesRESUMO
OBJECTIVE: To estimate the prevalence of delayed- initiation (DI) of antiretroviral therapy (ART) for people with HIV attended at the Ministry of Health (SS, for its initials in Spanish) in Mexico, and to describe its behavior over time (2008-2013) and differences by gender and age. MATERIALS AND METHODS: Descriptive and sectional study of people entering ART in the period 2008-2013 in the SS. The prevalence of DI ART (CD4+ <200 cells/ml) was estimated and differences according to sex and age were analyzed. RESULTS: The DI ART prevalence was 49%, having decreased 10% in the period. In men was 4.8% and 24.5% in women (p<0.01). The 15 to 29 years group also showed a decrease. CONCLUSIONS: Despite the decrease in ART DI prevalence, it still remains high. It is necessary to generate comprehensive screening strategies with multisectoral participation.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Tempo para o Tratamento/estatística & dados numéricos , Adolescente , Adulto , Contagem de Linfócito CD4 , Estudos Transversais , Diagnóstico Tardio , Feminino , Infecções por HIV/diagnóstico , Humanos , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Programas Nacionais de Saúde , Sistema de Registros , Adulto JovemRESUMO
Objetivo. Estimar la prevalencia de inicio tardío (IT) de terapia antirretroviral (TAR) de personas con VIH atendidas en la Secretaría de Salud (SS) en México y describir su comportamiento en el tiempo (2008-2013) así como las diferencias que presenta por sexo y grupo etario. Material y métodos. Estudio descriptivo transversal de personas que ingresaron a TAR en el periodo 2008-2013 en la SS. Se estimó la prevalencia de IT de TAR (CD4+ <200 células/ml) y se analizaron diferencias de acuerdo con sexo y edad. Resultados. La prevalencia de IT de TAR fue de 49% y se observó disminución de 10% en el periodo. En hombres fue de 4.8% y en mujeres de 24.5% (p<0.01). El grupo etario de 15 a 29 años también mostró disminución. Conclusiones. A pesar de la disminución de la prevalencia de IT de TAR, continúa siendo elevada. Es necesario generar estrategias de detección integrales con participación multisectorial.
Objective. To estimate the prevalence of delayed- initiation (DI) of antiretroviral therapy (ART) for people with HIV attended at the Ministry of Health (SS, for its initials in Spanish) in Mexico, and to describe its behavior over time (2008-2013) and differences by gender and age. Materials and methods. Descriptive and sectional study of people entering ART in the period 2008-2013 in the SS. The prevalence of DI ART (CD4+ <200 cells/ml) was estimated and differences according to sex and age were analyzed. Results. The DI ART prevalence was 49%, having decreased 10% in the period. In men was 4.8% and 24.5% in women (p<0.01). The 15 to 29 years group also showed a decrease. Conclusions. Despite the decrease in ART DI prevalence, it still remains high. It is necessary to generate comprehensive screening strategies with multisectoral participation.